SECTION 1. IDENTIFICATION

Product name : XOLAIR(R) Vials (150 mg)
Product code : 00010183117
Common name(s), synonym(s) of the substance : XOLAIR Lyophilized Vials 150 mg

Manufacturer or supplier’s details
Company name of supplier : Genentech, Inc.
Address : 1 DNA Way
South San Francisco, CA 94080
USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use
Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Combustible dust

GHS label elements
Signal Word : Warning
Hazard Statements : May form combustible dust concentrations in air.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>242138-07-4</td>
<td>57.3</td>
</tr>
<tr>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
<td>41.25</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS Number</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-Histidine monohydrochloride monohydrate</td>
<td>5934-29-2</td>
<td>0.8</td>
</tr>
<tr>
<td>L-Histidine</td>
<td>71-00-1</td>
<td>0.5</td>
</tr>
<tr>
<td>Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.</td>
<td>9005-64-5</td>
<td>0.15</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: Do not leave the victim unattended.

If inhaled:
Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact:
If on skin, rinse well with water.

In case of eye contact:
Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed:
Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

Most important symptoms and effects, both acute and delayed:
None known.

Notes to physician:
The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Specific hazards during firefighting:
No information available.

Hazardous combustion products:
In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
Sulfur oxides

Further information:
Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment:
Wear self-contained breathing apparatus for firefighting if
SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Avoid dust formation.

Environmental precautions: Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion: Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling: For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage: Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions: See label, package insert or internal guidelines.

Materials to avoid: No materials to be especially mentioned.

Storage temperature: 2 °C to 8 °C Protected from heat and light

Further information on storage stability: No decomposition if stored and applied as directed.

Packaging material: Suitable material: glass, glass bottles

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>242138-07-4</td>
<td>IOEL</td>
<td>0.02 mg/m3</td>
<td>Roche Industrial Hygiene Com-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mittee (RIHC)</td>
</tr>
<tr>
<td>.alpha.-D-</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m3</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>
Engineering measures : No data available

Personal protective equipment
Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection
In case of contact through splashing:
Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:
Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly. Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid, (lyophilized)

Color : white

Odor : Not applicable
## Odor Threshold
Not applicable

## pH
Not applicable

## Melting point/range
No data available

## Boiling point/boiling range
No data available

## Flash point
Does not flash

## Evaporation rate
No data available

## Self-ignition
No data available

## Upper explosion limit / Upper flammability limit
No data available

## Lower explosion limit / Lower flammability limit
No data available

## Vapor pressure
No data available

## Relative vapor density
Not applicable

## Relative density
No data available

## Solubility(ies)
- **Water solubility**: completely miscible
- **Solubility in other solvents**: No data available

## Partition coefficient: n-octanol/water
No data available

## Autoignition temperature
No data available

## Decomposition temperature
No data available

## Viscosity
- **Viscosity, dynamic**: Not applicable
- **Viscosity, kinematic**: Not applicable

## Explosive properties
No data available

## Oxidizing properties
No data available

### SECTION 10. STABILITY AND REACTIVITY

**Reactivity**: No dangerous reaction known under conditions of normal use.

**Chemical stability**: Stable under normal conditions.
Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created.

**Possibility of hazardous reactions**: Stable under recommended storage conditions. No hazards to be specially mentioned.

**Conditions to avoid**: No data available

**Incompatible materials**: No data available

**Hazardous decomposition products**: No data available

### SECTION 11. TOXICOLOGICAL INFORMATION

**Acute toxicity**
Not classified based on available information.

**Components:**

**Omalizumab:**

Acute oral toxicity: Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration): LD0 (Monkey): 200 mg/kg Application Route: i.v.

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Acute oral toxicity: LD50 Oral (Rat): 29,700 mg/kg

**Skin corrosion/irritation**
Not classified based on available information.

**Serious eye damage/eye irritation**
Not classified based on available information.

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Omalizumab:**

Genotoxicity in vitro: Test Type: Ames test
Test system: Salmonella typhimurium
Metabolic activation: with and without metabolic activation
Result: negative
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

Version 2.0
Revision Date: 11-08-2022
Date of last issue: 02-07-2020
Date of first issue: 02-07-2020

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Genotoxicity in vitro:
Test Type: In vitro mammalian cell gene mutation test
Result: negative

Carcinogenicity
Not classified based on available information.

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Remarks:
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:
Omalizumab:
Effects on fetal development:
Species: cynomolgus monkey, female
Application Route: s.c.
General Toxicity Maternal: NOAEL: 75 mg/kg bw/day
Embryo-fetal toxicity: NOAEL: 75 mg/kg bw/day
Result: No adverse effects.

STOT-single exposure
Not classified based on available information.

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Assessment:
The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure
Not classified based on available information.

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Assessment:
The substance or mixture is not classified as specific target organ toxicant, repeated exposure.
Repeated dose toxicity

Components:
Omalizumab:
Species: cynomolgus monkey
LOEL: 30 mg/kg/w
Application Route: s.c.
Exposure time: 26 Weeks

Aspiration toxicity
Not classified based on available information.

Components:
.alpha.-D-Glucopyranoside, beta.-D-fructofuranosyl:
No data available

Further information

Components:
Omalizumab:
Remarks: anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

.alpha.-D-Glucopyranoside, beta.-D-fructofuranosyl:
Remarks: Health injuries are not known or expected under normal use.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
.alpha.-D-Glucopyranoside, beta.-D-fructofuranosyl:

Ecotoxicology Assessment
Acute aquatic toxicity: This product has no known ecotoxicological effects.
Chronic aquatic toxicity: This product has no known ecotoxicological effects.
Toxicity Data on Soil: Not expected to adsorb on soil.
Other organisms relevant to the environment: No data available

Persistence and degradability

Components:
Omalizumab:
Biodegradability: Result: Globular proteins are generally well biodegradable

Bioaccumulative potential

Components:

Omalizumab:
Partition coefficient: n-octanol/water: Remarks: No data available

.\alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Partition coefficient: n-octanol/water: log Pow: -3.7 (68 °F / 20 °C)

Mobility in soil
No data available

Other adverse effects

Product:
Ozone-Depletion Potential: Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:

Omalizumab:
Additional ecological information: Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

SECTION 15. REGULATORY INFORMATION

**CERCLA Reportable Quantity**
This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**
This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**
This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards**
- Combustible dust

**SARA 313**
- This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**Clean Air Act**
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMII Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**
This product does not contain any Hazardous Substances listed under the U.S. Clean Water Act, Section 311, Table 116.4A.
This product does not contain any Hazardous Chemicals listed under the U.S. Clean Water Act, Section 311, Table 117.3.
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307.
This product does not contain any priority pollutants related to the U.S. Clean Water Act.
US State Regulations

Massachusetts Right To Know
.\alpha.-D-Glucopyranoside, .\beta.-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know
Omalizumab
.\alpha.-D-Glucopyranoside, .\beta.-D-fructofuranosyl 242138-07-4

Maine Chemicals of High Concern
Product does not contain any listed chemicals

Vermont Chemicals of High Concern
Product does not contain any listed chemicals

Washington Chemicals of High Concern
Product does not contain any listed chemicals

California Permissible Exposure Limits for Chemical Contaminants
.\alpha.-D-Glucopyranoside, .\beta.-D-fructofuranosyl 57-50-1

The ingredients of this product are reported in the following inventories:

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL:
      Omalizumab
      L-Histidine monohydrochloride monohydrate

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory

TSCA : Product contains substance(s) not listed on TSCA inventory.

TECI : Not in compliance with the inventory

TSCA list
No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

Version 2.0
Revision Date: 11-08-2022
Date of last issue: 02-07-2020
Date of first issue: 02-07-2020

NFPA 704:

<table>
<thead>
<tr>
<th>FLAMMABILITY</th>
<th>HEALTH</th>
<th>INSTABILITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>/</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>/</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH: USA, ACGIH Threshold Limit Values (TLV)
NIOSH REL: USA, NIOSH Recommended Exposure Limits
OSHA P0: USA, Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1: USA, Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA: 8-hour, time-weighted average
NIOSH REL / TWA: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA: 8-hour time weighted average
OSHA Z-1 / TWA: 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ErC - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office
SAFETY DATA SHEET

XOLAIR(R) Vials (150 mg)

Version: 2.0
Revision Date: 11-08-2022
Date of last issue: 02-07-2020
Date of first issue: 02-07-2020

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 11-08-2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104